Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01564407 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures
A Phase 1 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01564407 is a Phase 1 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 15 participants.
The verdict
NCT01564407, a Phase 1 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of ICX-RHY-013 in the treatment of stable, restrictive scars in subjects who have suffered a burn injury. Evaluation will be achieved through regular assessment of adverse events, vital signs, blood work monitoring and laboratory analysis cellular properties of the scar through biopsy. The secondary objectives of this study are to evaluate improvement in symptoms of scars including reduced pain, discomfort and itching, improvement in mobility and daily function, improvement in appearance and scar texture.
Interventions
- DRUG ICX-RHY-013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01564407
The ClinicalTrials.gov registry entry for NCT01564407 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ICX-RHY-013 is the first listed.
NCT01564407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01564407 about?
NCT01564407 is a clinical study titled "A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures". The primary objective of this study is to evaluate the safety of ICX-RHY-013 in the treatment of stable, restrictive scars in subjects who have suffered a burn injury. Evaluation will be achieved through regular assessment of adverse events, vital signs, blood work monitoring and laboratory analysis...
What is the current status of trial NCT01564407?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2011-01. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01564407?
The interventions under investigation include: ICX-RHY-013 (DRUG).
Who is sponsoring clinical trial NCT01564407?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.